Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206540596> ?p ?o ?g. }
- W4206540596 abstract "The fast diffusion of the SARS-CoV-2 pandemic have called for an equally rapid evolution of the therapeutic options.The Human recombinant monoclonal antibodies (mAbs) have recently been approved by the Food and Drug Administration (FDA) and by the Italian Medicines Agency (AIFA) in subjects aged ≥12 with SARS-CoV-2 infection and specific risk factors.Currently the indications are specific for the use of two different mAbs combination: Bamlanivimab+Etesevimab (produced by Eli Lilly) and Casirivimab+Imdevimab (produced by Regeneron).These drugs have shown favorable effects in adult patients in the initial phase of infection, whereas to date few data are available on their use in children.AIFA criteria derived from the existing literature which reports an increased risk of severe COVID-19 in children with comorbidities. However, the studies analyzing the determinants for progression to severe disease are mainly monocentric, with limited numbers and reporting mostly generic risk categories.Thus, the Italian Society of Pediatrics invited its affiliated Scientific Societies to produce a Consensus document based on the revision of the criteria proposed by AIFA in light of the most recent literature and experts' agreement.This Consensus tries to detail which patients actually have the risk to develop severe disease, analyzing the most common comorbidities in children, in order to detail the indications for mAbs administration and to guide the clinicians in identifying eligible patients." @default.
- W4206540596 created "2022-01-26" @default.
- W4206540596 creator A5003114766 @default.
- W4206540596 creator A5008622009 @default.
- W4206540596 creator A5015347683 @default.
- W4206540596 creator A5021755822 @default.
- W4206540596 creator A5034234671 @default.
- W4206540596 creator A5034637370 @default.
- W4206540596 creator A5043720811 @default.
- W4206540596 creator A5043791446 @default.
- W4206540596 creator A5046801644 @default.
- W4206540596 creator A5048154764 @default.
- W4206540596 creator A5055022644 @default.
- W4206540596 creator A5065088613 @default.
- W4206540596 creator A5068687552 @default.
- W4206540596 creator A5076016730 @default.
- W4206540596 creator A5078435232 @default.
- W4206540596 creator A5082103373 @default.
- W4206540596 creator A5083763991 @default.
- W4206540596 creator A5088115920 @default.
- W4206540596 creator A5088302605 @default.
- W4206540596 creator A9999999999 @default.
- W4206540596 date "2022-01-12" @default.
- W4206540596 modified "2023-10-05" @default.
- W4206540596 title "Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement" @default.
- W4206540596 cites W1972105569 @default.
- W4206540596 cites W1995891872 @default.
- W4206540596 cites W3018047057 @default.
- W4206540596 cites W3018910405 @default.
- W4206540596 cites W3022649665 @default.
- W4206540596 cites W3023595849 @default.
- W4206540596 cites W3025356234 @default.
- W4206540596 cites W3025844765 @default.
- W4206540596 cites W3028399919 @default.
- W4206540596 cites W3034102493 @default.
- W4206540596 cites W3036096355 @default.
- W4206540596 cites W3036105720 @default.
- W4206540596 cites W3037183278 @default.
- W4206540596 cites W3040477964 @default.
- W4206540596 cites W3044220214 @default.
- W4206540596 cites W3047144258 @default.
- W4206540596 cites W3048704086 @default.
- W4206540596 cites W3080128017 @default.
- W4206540596 cites W3081482126 @default.
- W4206540596 cites W3087065641 @default.
- W4206540596 cites W3087862874 @default.
- W4206540596 cites W3088256443 @default.
- W4206540596 cites W3088841124 @default.
- W4206540596 cites W3089197684 @default.
- W4206540596 cites W3092364459 @default.
- W4206540596 cites W3095678196 @default.
- W4206540596 cites W3096658347 @default.
- W4206540596 cites W3098914336 @default.
- W4206540596 cites W3101104830 @default.
- W4206540596 cites W3103952970 @default.
- W4206540596 cites W3105812499 @default.
- W4206540596 cites W3106806506 @default.
- W4206540596 cites W3106976909 @default.
- W4206540596 cites W3107960025 @default.
- W4206540596 cites W3108213766 @default.
- W4206540596 cites W3109136263 @default.
- W4206540596 cites W3110140393 @default.
- W4206540596 cites W3110755304 @default.
- W4206540596 cites W3111431752 @default.
- W4206540596 cites W3111635301 @default.
- W4206540596 cites W3112389441 @default.
- W4206540596 cites W3112745632 @default.
- W4206540596 cites W3113049899 @default.
- W4206540596 cites W3119095815 @default.
- W4206540596 cites W3120779559 @default.
- W4206540596 cites W3122861027 @default.
- W4206540596 cites W3123498813 @default.
- W4206540596 cites W3125266951 @default.
- W4206540596 cites W3127817567 @default.
- W4206540596 cites W3133612260 @default.
- W4206540596 cites W3133669355 @default.
- W4206540596 cites W3134421837 @default.
- W4206540596 cites W3136033869 @default.
- W4206540596 cites W3136462056 @default.
- W4206540596 cites W3138753415 @default.
- W4206540596 cites W3152791742 @default.
- W4206540596 cites W3153664678 @default.
- W4206540596 cites W3158750369 @default.
- W4206540596 cites W3159702338 @default.
- W4206540596 cites W3168877626 @default.
- W4206540596 cites W3172793935 @default.
- W4206540596 cites W3173119869 @default.
- W4206540596 cites W3178963577 @default.
- W4206540596 cites W3184115223 @default.
- W4206540596 cites W3184573940 @default.
- W4206540596 cites W3199488937 @default.
- W4206540596 doi "https://doi.org/10.1186/s13052-021-01187-1" @default.
- W4206540596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35022088" @default.
- W4206540596 hasPublicationYear "2022" @default.
- W4206540596 type Work @default.
- W4206540596 citedByCount "9" @default.
- W4206540596 countsByYear W42065405962022 @default.
- W4206540596 countsByYear W42065405962023 @default.
- W4206540596 crossrefType "journal-article" @default.
- W4206540596 hasAuthorship W4206540596A5003114766 @default.